The effects of erythropoiesis stimulating therapy for anemia in chronic heart failure: A meta-analysis of randomized clinical trials

The Prevalence and Management of Anemia in Chronic Kidney Disease Patients: Result from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD)

“…The intravenous iron supplement was given in only 1.9% and 7.9% among the applicable patients according to KDIGO guidelines and KNHIS coverage, respectively. However, the utilization pattern of iron agents and ESAs in the clinical setting can be influenced by more complex factors, such as the concern about the safety of iron and ESA treatment, socio-economic status of the patients, and physician's preferences (272829). …”

Effectiveness of erythropoietin supplementation against chronic heart failure with anemia, and its effect on serum hypersensitive C reaction protein, homocysteic acid and Btype natriuretic peptide

“…LVEF, LVEDD, LVESD, cardiac function grading, and 6-min walking distance in the observation group after treatment were significantly higher than corresponding values in the control group, indicating that EPO adjuvant therapies can improve clinical outcomes in patients with CHF and anemia. However, results from other studies [20] suggest that high dose of EPO should be avoided because even if EPO is not associated with increases in death rate and cardiovascular adverse events, the risk of thrombosis is increased.…”

“…In 1989, the first recombinant human erythropoietin agent (rhEPO) was used in clinical practice, and subsequently new EPO drugs have been constantly upgraded and increasingly widely used in the treatment of anemia because they improve the treatment outcomes of anemic patients [7,8]. In the present study, CHF patients with anemia were treated by exogenouslysupplemented erythropoietin, and changes in serum levels of hs-CRP, Hcy and BNP were determined before and after treatment.…”

Blood counts: targeting anaemia in patients with heart failure

“…More severe anaemia is associated with increasing rate of all‐cause mortality 2 . Despite decades spent identifying mechanisms that contribute to the presence of anaemia in patients with HF, attempts directed at ameliorating the putatively detrimental effects of anaemia have not been met with overwhelming success, and in the case of erythropoiesis‐stimulating agents have yielded unfavourable results 3 …”

“…2 Despite decades spent identifying mechanisms that contribute to the presence of anaemia in patients with HF, attempts directed at ameliorating the putatively detrimental effects of anaemia have not been met with overwhelming success, and in the case of erythropoiesis-stimulating agents have yielded unfavourable results. 3 The landmark Dapagliflozin and Prevention of Adverseoutcomes in Heart Failure (DAPA-HF) trial demonstrated that addition of the sodium-glucose co-transporter 2 inhibitor (SGLT2i) dapagliflozin to optimal medial therapy for HF with reduced ejection fraction (HFrEF) resulted in a 26% reduction in the combined risk of cardiovascular death, hospitalization for HF, or urgent visit for worsening HF. 4 The magnitude of benefit on the primary composite endpoint was similar in patients with and without diabetes and those with or without ischaemic heart disease.…”